Presbyterian Medical Center Go

Coronary artery disease

Here are the current clinical trials for coronary artery disease.

REGULATE

A Randomized, Open-Label, Multi-Center, Active-Controlled, Parallel Group Study to Determine the Efficacy and Safety of the Reg1 Anticoagulation System Compared to Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention

Principal investigator: Dr. Michael Miller

What is the purpose of the study?

To determine the efficacy of REG1 compared to bivalirudin in patients with coronary artery disease (CAD) undergoing Percutaneous Coronary Intervention (PCI) for preventing the composite of death, nonfatal myocardial infarction, nonfatal stroke and urgent target lesion revascularization (TLR) through Day 3.

Who is eligible?

Patients who qualify for a percutaneous coronary artery revascularization procedure and meet all the inclusion and none of the exclusion criteria required by the study.

For more information, contact:

Dr. Michael Miller
Phone: 704-264-1400

Link to the current ClinicalTrials.gov record »


GLAGOV

Global Assessment of plaque regression with a PCSK9 antibody as measured by intravascular ultrasound.

Principal investigator: Dr. Michael Miller

What is the purpose of the study?

To evaluate the effect of AMG 145 on the change in burden of coronary atherosclerosis as measured by percent atheroma volume in subjects with coronary artery disease requiring angiography for a clinical indication who are taking atorvastatin.

Who is eligible?

Patients that are requiring coronary angiography for further clinical evaluation. Patient must meet all inclusion and none of the exclusion criteria required by the study.

For more information, contact:

Dr. Michael Miller
Phone: 704-264-1400

Link to the current ClinicalTrials.gov record »